Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

That’s why Moderna’s vaccine currently targets three viruses at once, and it has another vaccine in earlier stages of development that can target five. This is similar to seasonal flu vaccines ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

The S&P 500 fell 1.1% on Tuesday, Jan. 7, as U.S. manufacturing data reinvigorated concerns about inflation and the interest ...

Evercore ISI lowered the firm’s price target on Moderna (MRNA) to $50 from $60 and keeps an In Line rating on the shares. The firm is updating ...

Investing.com -- Morgan Stanley slashed its price target on Moderna Inc (BMV ... ongoing competitive pressures in the vaccine market. The firm noted Moderna's reduced 2024 sales forecast of ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

Moderna (NASDAQ:MRNA – Free Report) had its price objective decreased by Morgan Stanley from $70.00 to $38.00 in a report issued on Wednesday,Benzinga reports. Morgan Stanley currently has an equal ...

Goldman Sachs analyst Salveen Richter downgraded Moderna (NASDAQ:MRNA) stock from Buy to Neutral, significantly reducing the price target to $51 from the previous $99. Trading at $44.94, the stock has ...

Moderna’s vaccine is designed to target H5 and H7 avian influenza viruses. The company plans to move into phase 3 clinical trials to test the vaccine in a larger group of people after receiving ...